Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW. Park SI, et al. Among authors: axtman a. Blood. 2010 Nov 18;116(20):4231-9. doi: 10.1182/blood-2010-05-282327. Epub 2010 Aug 11. Blood. 2010. PMID: 20702781 Free PMC article.
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW. Pagel JM, et al. Among authors: axtman a. Blood. 2011 Jul 21;118(3):703-11. doi: 10.1182/blood-2011-04-347039. Epub 2011 May 25. Blood. 2011. PMID: 21613259 Free PMC article.
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur DS, Stayton PS, Orgun N, Hylarides M, Buchegger F, Kenoyer AL, Axtman A, Gopal AK, Green DJ, Pagel JM, Press OW. Park SI, et al. Among authors: axtman a. Clin Cancer Res. 2011 Dec 1;17(23):7373-82. doi: 10.1158/1078-0432.CCR-11-1204. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976541 Free PMC article.
Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2.
Ong HW, Yang X, Smith JL, Taft-Benz S, Howell S, Dickmander RJ, Havener TM, Sanders MK, Brown JW, Couñago RM, Chang E, Krämer A, Moorman NJ, Heise M, Axtman AD, Drewry DH, Willson TM. Ong HW, et al. Among authors: axtman ad. Molecules. 2024 Sep 2;29(17):4158. doi: 10.3390/molecules29174158. Molecules. 2024. PMID: 39275006 Free PMC article.
Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.
Bashore FM, Min SM, Chen X, Howell S, Rinderle CH, Morel G, Silvaroli JA, Wells CI, Bunnell BA, Drewry DH, Pabla NS, Ultanir SK, Bullock AN, Axtman AD. Bashore FM, et al. Among authors: axtman ad. ACS Med Chem Lett. 2024 Jul 3;15(8):1325-1333. doi: 10.1021/acsmedchemlett.4c00219. eCollection 2024 Aug 8. ACS Med Chem Lett. 2024. PMID: 39140040 Free PMC article.
More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-a]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication.
Ong HW, Yang X, Smith JL, Dickmander RJ, Brown JW, Havener TM, Taft-Benz S, Howell S, Sanders MK, Capener JL, Couñago RM, Chang E, Krämer A, Moorman NJ, Heise M, Axtman AD, Drewry DH, Willson TM. Ong HW, et al. Among authors: axtman ad. J Med Chem. 2024 Jul 25;67(14):12261-12313. doi: 10.1021/acs.jmedchem.4c00962. Epub 2024 Jul 3. J Med Chem. 2024. PMID: 38959455 Free PMC article.
Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.
Bashore FM, Min SM, Chen X, Howell S, Rinderle CH, Morel G, Silvaroli JA, Wells CI, Bunnell BA, Drewry DH, Pabla NS, Ultanir SK, Bullock AN, Axtman AD. Bashore FM, et al. Among authors: axtman ad. bioRxiv [Preprint]. 2024 May 14:2024.05.12.593776. doi: 10.1101/2024.05.12.593776. bioRxiv. 2024. Update in: ACS Med Chem Lett. 2024 Jul 03;15(8):1325-1333. doi: 10.1021/acsmedchemlett.4c00219 PMID: 38798634 Free PMC article. Updated. Preprint.
Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.
Asquith CRM, East MP, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells CI, Axtman AD, Drewry DH, Tizzard GJ, Poso A, Willson TM, Johnson GL. Asquith CRM, et al. Among authors: axtman ad. Eur J Med Chem. 2024 May 5;271:116357. doi: 10.1016/j.ejmech.2024.116357. Epub 2024 Apr 2. Eur J Med Chem. 2024. PMID: 38636130 Free PMC article.
53 results